Published in AIDS Weekly, July 15th, 2002
As the exclusive licensee of worldwide rights to the technology disclosed in this patent, Synergy strengthens its position in the vaccine market through the usage of the complexes of antigens and alpha-2-macroglobulin (SynerVax adjuvant) as vaccine candidates.
Synergy Vaccines is currently evaluating the use of the SynerVax adjuvant system with a wide variety of vaccine...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.